Estimating the mesorectal fascia in MRI.

Inf Process Med Imaging

Wolfson Medical Vision Laboratory, Department of Engineering Science, University of Oxford, Oxford, OXI 3PJ, UK.

Published: August 2007

Apart from chemoradiotherapy, surgery by total mesorectal resection is currently the only curative therapy for colorectal cancer. However, this often has a poor outcome, especially if there are affected lymph nodes too close to the resection boundary. The circumferential resection margin (CRM) is defined as the shortest distance from an affected region to the mesorectal fascia (MF), and should be at least 1 mm. However, this 3D distance is normally estimated in 2D (from image slices) and takes no account of uncertainty of the position of the MF. We describe a system able to estimate the location of the MF with a measure at each point along it of the uncertainty in location, and which then estimates the CRM in three dimensions. The MF localisation algorithm combines anatomical knowledge with a level set method based on: a non-parametric representation of the distribution of intensities, and the use of the monogenic signal to detect portions of the boundary.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-540-73273-0_54DOI Listing

Publication Analysis

Top Keywords

mesorectal fascia
8
estimating mesorectal
4
fascia mri
4
mri apart
4
apart chemoradiotherapy
4
chemoradiotherapy surgery
4
surgery total
4
total mesorectal
4
mesorectal resection
4
resection currently
4

Similar Publications

This manuscript focused on the surgical challenge of urinary and sexual dysfunction after rectal cancer surgery based on the interesting results demonstrated by the observational study of Chen , which was published in the . Urinary dysfunction occurs in one-third of patients treated for rectal cancer. Surgical nerve damage is the main cause of urinary dysfunction.

View Article and Find Full Text PDF

Contact X-ray Brachytherapy as a Boost Therapy After Neoadjuvant (Chemo)Radiation in High-Risk Locally Advanced Rectal Cancer.

Int J Radiat Oncol Biol Phys

December 2024

Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool; Papillon Suite, The Clatterbridge Cancer Centre National Health Service Foundation Trust, Bebington, Wirral, United Kingdom. Electronic address:

Purpose: Radical surgery following neoadjuvant therapy is the standard of care for locally advanced rectal cancer. A contact x-ray brachytherapy (CXB) boost can alternatively be used to treat residual disease postneoadjuvant (chemo)radiation, especially in patients who are not suitable for or do not wish to have surgery. Its role has mostly been studied to date in low- to intermediate-risk patients.

View Article and Find Full Text PDF

Background: The main purpose of this study was to determine the feasibility of sparing the rectoprostatic fascia (RPF) in adult male cadavers and in adult male patients who underwent total mesorectal excision (TME) for rectal cancer. A secondary objective was to evaluate urogenital function following rectal cancer surgery, pathologic, and oncologic outcomes.

Methods: In accordance with PRISMA guidelines, we performed a systematic review with an a priori design to identify relevant studies via MESH terms and keywords.

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed how well three radiologists agreed on MRI evaluations for staging and restaging rectal cancer in 239 patients, particularly after neoadjuvant therapy.
  • The findings showed moderate to high interobserver agreement on various MRI parameters, with specific focus on tumor distance from the mesorectal fascia and lymph node involvement being significant predictors of locoregional recurrence.
  • Ultimately, the analysis highlighted the importance of lymph node restaging and its correlation with locoregional recurrence rates, indicating that changes in lymph node status can influence patient outcomes.
View Article and Find Full Text PDF

Background: Total neoadjuvant treatment (TNT) for locally advanced rectal cancer (LARC) increases pathologic complete response (pCR) rate and reduces the risk of systemic recurrences over chemoradiotherapy (CRT) in randomised trials, e.g., the RAPIDO trial.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!